Application: Minimal residual disease detection and recurrence monitoring
Approach: Tumor-informed WES plus personalized ctDNA tracking
Sensitivity: LoD down to 0.0025%
Clinical Evidence: Validated in large NSCLC cohorts (LUNGCA, EVIDENCE studies)
Application: Minimal residual disease detection and recurrence monitoring
Approach: Tumor-informed WES plus personalized ctDNA tracking
Sensitivity: LoD down to 0.0025%
Clinical Evidence: Validated in large NSCLC cohorts (LUNGCA, EVIDENCE studies)